Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The country is sixth among the most affected countries by active cases
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
